Tag:
AstraZeneca
Latest Headlines
Latest Headlines
Safety scare with AstraZeneca's diabetes drug could shake up the DPP-4 field
The FDA raised some alarming concerns tied to AstraZeneca's Onglyza ahead of a committee meeting to discuss the safety of so-called DPP-4 inhibitors, sounding a worrying note for a blockbuster class of drugs.
AZ's Onglyza has most to lose at FDA safety confab, analysts say
FDA experts will grill a couple of diabetes meds next Tuesday, and the outcome of that debate could put a damper on sales. The drugs: AstraZeneca's Onglyza and Takeda's Nesina, both DPP-4 blood sugar-fighters. The questions: Do they really increase the risk of heart failure? And if so, what's to be done about it?
Regulus surges after AstraZeneca snags rights to NASH drug
Shares of Regulus spiked 10% Tuesday afternoon after its Big Pharma partner AstraZeneca stepped up to grab rights to a preclinical drug candidate for NASH with plans to steer it into clinical studies.
Regulus surges after AstraZeneca snags rights to preclinical NASH drug
Shares of Regulus spiked 10% Tuesday afternoon after its Big Pharma partner AstraZeneca stepped up to grab rights to a preclinical drug candidate for NASH with plans to steer it into clinical studies.
AstraZeneca gets FDA nod for alternative administration of oral heart med
AstraZeneca's Brilinta can now be crushed and mixed with water or delivered through the nose via a tube, the FDA said, in a move designed to help patients who are unable to swallow the 90-mg tablets whole.
AstraZeneca razes R&D facilities in Delaware
AstraZeneca's former R&D operations in Delaware, abandoned years ago in the pharma giant's ongoing restructuring and downsizing, are being razed.
WuXi and AstraZeneca roll toward Chinese approval with an arthritis drug
Partners WuXi PharmaTech and AstraZeneca's MedImmune are on schedule with a rheumatoid arthritis-treating antibody designed for the Chinese market, as the country's regulators have accepted their application.
Yale team says failed AstraZeneca drug shows promise in Alzheimer's
AstraZeneca's AZD0530 proved a disappointment as a new drug for solid tumors, but a Yale team says it may prove more effective in a new program for Alzheimer's.
Myriad extends companion Dx deal with AstraZeneca to pancreatic cancer
Myriad Genetics is expanding its companion diagnostics partnership with AstraZeneca, planning to use Myriad's BRACAnalysis test to see which metastatic pancreatic cancer patients respond to AstraZeneca's Lynparza (olaparib).
Yale team says failed AstraZeneca drug shows promise in Alzheimer's
AstraZeneca's AZD0530 proved a disappointment as a new drug for solid tumors, but a Yale team says it may prove more effective in a new program for Alzheimer's.
